Welcome to our dedicated page for Adastra Holdings news (Ticker: XTXXF), a resource for investors and traders seeking the latest updates and insights on Adastra Holdings stock.
News and disclosures about Adastra Holdings Ltd. (XTXXF) focus on its role as a cannabis processor and manufacturer of ethnobotanical and cannabis products for lawful adult-use and medical markets. Adastra’s updates frequently highlight its Health Canada licensed operations, its concentrates brands Phyto Extractions and Endgame Extracts, and its distribution reach through Canadian retailers.
Investors and observers following Adastra’s news can expect coverage of strategic transactions, corporate governance changes and capital structure developments. Recent releases describe the sale of subsidiaries such as Adastra Labs Holdings (2019) Ltd., 1178562 B.C. Ltd., Adastra Brands Inc., and 1225140 B.C. Ltd. (dba Perceive MD), which the company states are intended to strengthen its balance sheet, reduce debt and streamline operations while maintaining access to its existing facility and brand trademarks through lease and licensing agreements.
Adastra’s news flow also includes information on board and management changes, such as director appointments and resignations, as well as updates on interim and permanent leadership roles. The company has issued clarifications on its management structure and described consulting arrangements for financial reporting and budgeting support.
Capital markets updates, including the announcement of a proposed 10:1 share consolidation on the Canadian Securities Exchange, are another recurring theme in Adastra’s communications. In addition, the company provides details on shareholder meetings, voting procedures and access to proxy materials through Canadian securities platforms. Readers who follow Adastra’s news page can track how the company manages its cannabis processing operations, brand portfolio and corporate structure within a regulated industry environment.
Adastra Holdings (CSE: XTRX, FSE: D2EP), a prominent cannabis processor and producer, announced a proposed 10:1 share consolidation pending approval from the Canadian Securities Exchange (CSE). This consolidation will reduce the number of issued and outstanding common shares from 55,970,547 to approximately 5,597,055. Proportionate adjustments will be made to outstanding options, and no fractional shares will be issued, as fractions will be rounded to the nearest whole number. Subject to CSE approval, the consolidated shares are expected to begin trading on or around October 15, 2024, under the trading symbol "XTRX". Registered shareholders will receive a letter of transmittal from National Securities Administrators (NSA) with instructions on how to exchange their pre-consolidation shares. Non-registered shareholders should contact their intermediaries for further details. The letter of transmittal will be available on SEDAR+ and the company's website.
Adastra Holdings (CSE: XTRX) (FSE: D2E), a leading cannabis processor and producer of top Canadian concentrates brands, has announced the resignation of Lachlan McLeod from his roles as Chief Financial Officer and Corporate Secretary, effective October 5th. The resignation is effective immediately, and the company is currently in the process of selecting and approving new candidates to fill these positions. Adastra emphasizes its commitment to ensuring a smooth transition and maintaining continuity in these important roles.
Adastra Holdings (CSE: XTRX) (FSE: D2E), a leading cannabis processor and producer, has announced the resignation of Lachlan McLeod from his roles as Interim CEO, CFO, and Corporate Secretary. McLeod's resignation as Interim CEO is effective immediately, while he will continue as CFO and Corporate Secretary until November 25, 2024, to ensure a smooth transition. The company is currently in the process of selecting and approving new candidates to fill these positions.
McLeod expressed confidence in Adastra's strong financial position for continued growth and success, and committed to working closely with the team to ensure a seamless transition. Adastra Holdings is known for its focus on product innovation and commercialization for adult-use and medical cannabis markets, producing two top Canadian concentrates brands.